LW-1017 (TRPML1 agonist)
Cognitive · TRPML1 agonist (autophagy)
Tier D+
Bottom line
Read Off Label grades LW-1017 (TRPML1 agonist) as D+ (3.7/10) based on preclinical evidence, med benefit magnitude, and a med-risk safety profile.
Lysoway Therapeutics.
Studied, labeled, or reported-use context: Oral; Phase 1 single/multiple ascending dose — Investigational; not individualized guidance.
Frontier potential — editorial judgment, not evidence
This is a separate axis from the grade above. It asks a different question: if this worked in humans, how much would it matter? It is our judgment, it is not part of the composite score, and it cannot raise a grade. A high number here is a statement about the idea, not about whether it works or whether anyone should take it.
What the ceiling rests on
Targets lysosomal function directly — TRPML1 agonism enhances lysosomal biogenesis and autophagic flux, and loss of proteostasis is one of the better-supported hallmarks of ageing. Acting on the disposal machinery rather than a single aggregate is a mechanistically attractive position, and it has reached first-in-human.
Why it may not get there
Everything supporting the ceiling is preclinical. Enhancing autophagy systemically has plausible downsides, including effects on tumour-cell survival, and no human efficacy or safety data have been published. First-in-human status is a starting line, not evidence.
What would change this Published Phase 1 safety and target-engagement data.
What the evidence says
Lysoway Therapeutics. First TRPML1 agonist in the clinic, first participant dosed May 2026 in a Phase 1 SAD/MAD study (Melbourne) in healthy volunteers, developed for Alzheimer's/Parkinson's. A clean safety and target-engagement readout would be early human proof that pharmacologically boosting autophagy works. No published human data yet. Frontier. Company-sponsored.
Mechanism
Brain-penetrant small-molecule agonist of TRPML1, a lysosomal calcium channel gating autophagy-lysosomal clearance, the proteostasis pathway underlying rapamycin, spermidine and fasting; aimed at neurodegenerative protein aggregation.
Studied, labeled, or reported dose & route
Oral; Phase 1 single/multiple ascending dose
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about LW-1017 (TRPML1 agonist)'s effects?
- Read Off Label rates the evidence for LW-1017 (TRPML1 agonist) as Preclinical and the benefit magnitude as med, producing an overall grade of D+ (3.7/10). Lysoway Therapeutics.
- What safety findings are reported for LW-1017 (TRPML1 agonist)?
- LW-1017 (TRPML1 agonist) has a med risk profile in the database. Med (first-in-human; human safety not yet established) Legal status: Investigational (Phase 1 SAD/MAD).
- What doses or routes are reported for LW-1017 (TRPML1 agonist)?
- Oral; Phase 1 single/multiple ascending dose This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does LW-1017 (TRPML1 agonist) work?
- Brain-penetrant small-molecule agonist of TRPML1, a lysosomal calcium channel gating autophagy-lysosomal clearance, the proteostasis pathway underlying rapamycin, spermidine and fasting; aimed at neurodegenerative protein aggregation.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.